B2i Digital

B2i Digital The Capital Markets Matchmaker℠. They need an integrated team that takes a wholistic approach to their company's capital raising and investor awareness goals.

B2i Digital partners with public companies, conferences, and advisors to connect investors and companies through digital marketing, investor conferences, and direct meetings. Our team brings together decades of experience from the disparate worlds of investor relations, investment banking and digital marketing. In the rapidly evolving capital markets landscape, CEOs can no longer rely on the typic

al siloed mentality and try to manage multiple vendors. Investors want accurate, factual, relevant, and timely information provided by the companies where they invest. No hype. Just facts. Plus, direct access to senior management. Our cross-functional team bridges the communication gap between CEOs and investors to meet the needs of both sides for a more transparent dialogue.

05/29/2026

ZenaTech Inc. (Nasdaq: ZENA) announces plans to pursue potential investment opportunities connected to the U.S. Department of War and Office of Strategic Capital, citing its NDAA-compliant ZenaDrone supply chain and prior paid trials with the U.S. Air Force and Navy Reserve.

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) announced that it plans to pursue opportunities from the U.S. Department of War following a recent Wall Street Journal article reporting that the Trump administration is in discussions with U.S. drone companies and would begin considering new investments in U.S.-based drone manufacturers. The Company said it believes ZenaDrone, its drone manufacturing subsidiary, is positioned to support U.S. government objectives focused on expanded domestic production, affordable and scalable autonomous systems, and national security, including initiatives supported through the Office of Strategic Capital (OSC).

ZenaTech, Inc. is a B2i Digital Featured Company. A dedicated profile page is coming soon at https://b2idigital.com/featured-companies.

“These are important opportunities as the demand for more advanced technology increases. We believe our defense platform provides true innovation in the market through our integrated suite of products that offer both flexibility and cost-consciousness, allowing for a leaner, precision-oriented line. We look forward to the opportunity to collaborate with the U.S. Defense Department and the Office of Strategic Capital toward a strategic investment intended to help us drive this technology into the future,” said Shaun Passley, PhD, ZenaTech CEO. “We intend to provide updates on our discussions as they develop.”

See the full release: https://www.globenewswire.com/news-release/2026/05/29/3303514/0/en/zenatech-to-pursue-new-investment-opportunities-connected-with-the-department-of-war-and-office-of-strategic-capital-following-reports-of-engagement-with-u-s-drone-makers.html

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/29/2026

The 16th Annual ROTH Capital Partners London Conference will be held at the Four Seasons Hotel London at Park Lane, June 16–18, 2026.

The ROTH London event is a B2i Digital Featured Conference. Learn more at https://b2idigital.com/roth-16th-annual-london-conference

This invitation-only event brings together 80+ public and private growth companies in sustainability, technology, energy, and natural resources with institutional investors for 1-on-1 and small-group meetings, plus social gatherings throughout the three-day program.

This year's agenda features a Market Overview from ROTH Chief Economist Michael Darda, Living In A Bear Market While Investing In A Bull Market from ROTH Chief Technical Strategist JC O'Hara, CAIA, CMT, and a Special Presentation, What Investors Need To Know In 2026, from Cathie Wood, Founder and CEO of ARK Investment Management.

As the Marketing Partner, B2i Digital supports visibility and investor engagement through its Marketing to Meetings℠ platform.

Registration requests (subject to approval by a ROTH representative): https://www.meetmax.com/sched/event_131899/conference_home.html

Credit to the team at ROTH for hosting: Byron Roth, Aaron Gurewitz, Isabel Mattson-Pain, Nazan Akdeniz, Otilia "Charo" Montano, Grace Deller, Amanda McAdams, Jesse Pichel, Robert Stephenson, Alexander Montano, Marc Lewis, Brady Fletcher, Philip Shen, Suji DeSilva, Craig Irwin, Gerry Sweeney, Tom Hayes, Justin Clare, CFA, Rohit Kulkarni, Joseph Reagor, Al Longfield, Chip Moore, CFA, Michael Guzman, Lev Seleznov and many others.

ROTH Capital Partners is a relationship-driven investment bank focused on growth companies and their investors. Learn more at https://www.roth.com.

B2i Digital connects emerging growth companies with investors through digital marketing campaigns, investor conferences, and targeted investor engagement programs. Discover more at https://b2idigital.com.

B2i Digital is the Marketing Partner of the 16th Annual ROTH London Conference. This content is for informational purposes only and should not be considered investment advice.

05/28/2026

ZenaTech Inc. (Nasdaq: ZENA) enters AI data center construction with ZenaWorx, a LiDAR-based VDC progress monitoring platform aimed at the North American AI data center market, which is projected to grow at a 30% CAGR through 2030.

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) announced its entry into the rapidly growing AI data center construction market with the initial development of ZenaWorx, a LiDAR-based Virtual Design and Construction (VDC) progress monitoring software. ZenaWorx uses drone-captured LiDAR data to build a detailed 3D digital map of a construction site, tracking ongoing progress and identifying deviations from planned design. The software will be jointly developed and offered through the Company’s Drone as a Service and Enterprise SaaS divisions.

ZenaTech, Inc. is a B2i Digital Featured Company. A dedicated profile page is coming soon at https://b2idigital.com/featured-companies.

The Company has identified a potential beta customer preparing to begin a several-hundred-acre AI data center construction project, with discussions currently at the negotiation stage. ZenaWorx is designed to improve accuracy and cost-effectiveness across the construction lifecycle, transforming drone and LiDAR-captured data into visual, analytics-driven construction progress insights.

“The AI data center market is experiencing unprecedented expansion as an important growth market for drone-powered surveying, analytics, and construction monitoring solutions,” said Shaun Passley, Ph.D., CEO of ZenaTech. “With the development of ZenaWorx we plan to support construction and infrastructure operators with advanced aerial data collection, LiDAR-based 3D analytics, and a scalable subscription-based service designed to improve visibility, efficiency, and cost-effectiveness of project ex*****on throughout the construction lifecycle.”

See the full release: https://www.zenatech.com/zenatech-enters-the-ai-data-center-construction-market-with-zenaworx-a-drone-based-3d-digital-progress-monitoring-software/

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/27/2026

Kolibri Global Energy Inc. (Nasdaq: KGEI, TSX: KEI) and CEO Wolf Regener presented at the Oil & Gas Virtual Investor Conference on April 16, 2026.

Kolibri Global Energy is a B2i Digital Featured Company. View their complete profile at https://b2idigital.com/kolibri-global-energy and follow Kolibri on X, Facebook, and LinkedIn.

Wolf closed with a summary of the capital approach:

• Target of debt below 1.0x Adjusted EBITDA, currently about 1.09x and expected to drop below 1.0x
• Roughly 650,000 shares repurchased under the NCIB at presentation time
• 2026 drilling moved up from June to April after oil prices firmed

On capital allocation, Wolf added: “This cash flow gives us options to return more capital to shareholders, drill more wells, or whatever else.”

https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5308536/kolibri-global-energy-inc-nasdaq-kgei?utm_source=b2i&utm_medium=marketing&utm_campaign=0426OilGasVIC

Kolibri is led by Wolf Regener, President and CEO, alongside a seasoned technical team including CFO Gary Johnson, CPA, MBA, Director of Engineering Dan Simpson, Senior Geologist Allan Hemmy, and Landman Dalia Lupita Isaac. The company is focused on developing its oil-rich Caney acreage in Oklahoma.

For additional details, please visit the Investors section of Kolibri’s website at: https://kolibrienergy.com/investors/.

Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted KGEI stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of KGEI or any security, and it is not intended to offer any opinion on KGEI as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.

05/27/2026

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has opened patient enrollment in RESET, its Phase 2a study of JOTROL in Parkinson’s disease, with first dosing expected shortly.

Jupiter Neurosciences is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/jupiter-neurosciences-1

Roughly 1.1 million Americans live with Parkinson’s disease, which still has no approved disease-modifying therapy. JOTROL is Jupiter’s enhanced-bioavailability resveratrol formulation, and RESET will evaluate its safety, tolerability, and pharmacokinetics in a randomized, placebo-controlled study.

Jupiter is also advancing a second CNS opportunity. The company signed a term sheet on May 20, 2026 for exclusive, perpetual U.S. rights to ALA-002, a next-generation psychedelic NCE from PharmAla Biotech that would broaden its CNS-focused pipeline if the transaction closes.

Trial and pipeline highlights:

• RESET (NCT07592767) is enrolling 30 patients across study centers in DC, Maryland, and Virginia
• The 12-week study randomizes patients to two JOTROL doses or placebo, with completion projected for the first half of 2027
• Phase 1 work showed roughly 9-fold higher plasma bioavailability than conventional resveratrol, measurable cerebrospinal fluid levels, and no serious adverse events, supporting FDA IND clearance in November 2025
• The proposed ALA-002 rights would add a patented psychedelic NCE to Jupiter’s CNS and neuroinflammation pipeline

Christer Rosén, Chief Executive Officer of Jupiter Neurosciences, commented, “With enrollment now underway in the Phase 2a RESET trial we have reached a critical operational milestone. We look forward to generating the clinical data needed to evaluate JOTROL’s potential and to serve patients, providers, and the broader scientific community.”

See the press release: https://www.globenewswire.com/news-release/2026/05/27/3301824/0/en/jupiter-neurosciences-announces-patient-enrollment-underway-in-phase-2a-reset-trial-in-parkinson-s-disease.html

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. Its lead program, JOTROL, a proprietary enhanced-bioavailability resveratrol formulation, is in a Phase IIa clinical trial for Parkinson’s disease. JUNS also commercializes Nugevia, a consumer longevity supplement.

Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marshall Hayward, Ph.D., Co-Founder and CSO. Learn more at www.jupiterneurosciences.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted JUNS stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/26/2026

BNB Plus Corp. (Nasdaq: BNBX) secures initial commitments for $4.1M of convertible preferred stock financing led by Silvermine Capital to support a strategic review.

BNB Plus Corp. (Nasdaq: BNBX) announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M. Including anticipated proceeds, the Company expects to hold over $16.4M in cash and digital assets, as valued on May 23, 2026.

BNB Plus Corp. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/bnbx.

Investors in the financing include Comstock Multichain Fund, an investment vehicle managed by Silvermine Capital Advisors, LLC, and Off the Chain, LP, alongside other digital-asset-native institutional investors. In conjunction with the financing, the Company will enter into an advisory arrangement with GlobalStake Infrastructure, LLC, a SOC 2 Type II certified Web3 infrastructure company, which will lead a comprehensive review of the Company’s business, assets, and capital structure.

The review will prioritize two value creation pathways: digital asset and AI infrastructure opportunities, including institutional yield generation; and a structured monetization assessment of LineaRx, Inc., the Company’s therapeutic DNA production subsidiary, which recently achieved profitability in Q2 FY2026. The review will be led by Richard Shorten, Founder of Silvermine and Chairman of GlobalStake.

Clay Shorrock, Chief Executive Officer of BNB Plus, noted, “This financing marks a deliberate step forward for BNBX and reflects investor confidence in our operational trajectory and the distinct value proposition of our business.”

See the full release: https://www.businesswire.com/news/home/20260525437108/en/

Transaction terms include two series of convertible preferred stock, both senior to common and convertible on a 1-for-1 basis. The Series B-1 Preferred Stock is priced at $1.05 per share, a 176% premium over the closing price of the Company’s common stock on May 22, 2026, with an 8.0% annual dividend and a 1.5x liquidation preference. Series B-1 investors will also receive three-year warrants with 100% coverage at an exercise price of $0.76.

BNB Plus Corp. is led by Clay Shorrock, Chief Executive Officer and President; and Beth Jantzen, Chief Financial Officer. The advisory team includes Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital, as Strategic Capital Markets Advisor; Patrick Horsman, CFA, as Chief Investment Officer; Joshua Kruger, as Chairman of the Board; and JR Pasch, as Strategic Advisor.

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/26/2026

Phio Pharmaceuticals (NASDAQ: PHIO) to present its INTASYL® siRNA platform and PH-762 program at the Renmark Live Virtual Non-Deal Roadshow on Thursday, May 28, 2026.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) will join Renmark Financial Communications’ Live Virtual Non-Deal Roadshow Series on Thursday, May 28, 2026, at 12 PM EDT. CEO and Chairman Robert Bitterman will present an overview of the Company’s INTASYL® siRNA gene silencing platform, including its lead clinical candidate PH-762 for the treatment of cutaneous carcinomas, followed by a live Q&A.

Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/phio-pharmaceuticals.

INTASYL is a proprietary RNA interference platform designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical candidate, PH-762, silences the PD-1 gene implicated in various forms of skin cancer and is being evaluated in a Phase 1b trial (NCT # 06014086) for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma as a potential non-surgical treatment.

“We look forward to participating in the Renmark Virtual Non-Deal Roadshow, where we will discuss why we believe INTASYL represents a differentiated and promising approach in immuno-oncology,” said Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

Register for the event: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-phio-Mbp9ao86qh

See the full release: https://phiopharma.com/phio-pharmaceuticals-announces-participation-in-the-renmark-financial-communications-live-virtual-non-deal-roadshow-series-5/

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company developing therapeutics through its proprietary INTASYL gene silencing technology. INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells, with lead candidate PH-762 advancing as a potential non-surgical treatment for skin cancers.

Phio is led by Robert Bitterman, CEO and Chairman of the Board.

Learn more at [www.phiopharma.com](https://www.phiopharma.com). Discover more emerging growth Featured Companies at [b2idigital.com](https://b2idigital.com).

Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/26/2026

Algorhythm Holdings (Nasdaq: RIME) subsidiary SemiCab signs a master service agreement with Onida Electronics, expanding its India network to 15 enterprise customers.

Algorhythm Holdings, Inc. (Nasdaq: RIME) announced that its SemiCab subsidiary signed a master service agreement with Onida Electronics, one of India’s most recognized consumer electronics brands.

Algorhythm Holdings is a B2i Digital Featured Company. See the full profile: https://b2idigital.com/algorhythm-holdings-1

Under the agreement, Onida will be able to use SemiCab’s freight network across domestic transportation lanes in India. The release notes:
- SemiCab now works with 15 enterprise customers across India
- The agreement adds to several recent contract expansions with existing customers and follows strong year-over-year revenue growth
- The platform is designed to improve truck utilization and reduce empty miles for shippers and carriers

“With surging diesel prices, shippers are under increasing pressure to control logistics costs while maintaining service levels,” said Gary Atkinson, CEO of Algorhythm Holdings. “SemiCab’s platform helps solve both by using AI to orchestrate freight networks more intelligently, reducing waste and improving efficiency across complex supply chains.”

See the press release at: https://algoholdings.com/press-release-details?newsId=3301184

Algorhythm Holdings, Inc. is a leading AI technology company focused on the growth and development of its SemiCab platform. Since 2020, SemiCab has enabled major retailers, brands, and transportation providers to address supply-chain challenges through its AI-enabled, cloud-based Collaborative Transportation Platform.

The company is led by Gary Atkinson, CEO, and Alex Andre, CFO. SemiCab is led by Ajesh Kapoor, CEO, and Vivek Sehgal, CPO. Learn more at https://algoholdings.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted RIME stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security.

05/21/2026

Genvor (OTCQB: GNVR) Appoints Donald Kalkofen as CFO to Support Dual-Market Growth Across Agriculture and Human Health

Genvor Inc. (OTCQB: GNVR) announced the appointment of Don Kalkofen as Chief Financial Officer. Mr. Kalkofen will lead Genvor’s financial strategy as the company advances its dual-market commercialization plans across agriculture and human health.

Genvor, Inc. is a B2i Digital Featured Company. Learn more at https://b2idigital.com/genvor.

Mr. Kalkofen brings more than 20 years of public-company finance leadership experience across biotechnology, financial services, and technology, with a track record of guiding companies through initial public offerings and complex capital markets transactions.

• Most recently served as CFO of Alpha Cognition, where he helped lead preparations for the company’s NASDAQ listing and build investor relations and audit infrastructure
• Previously served as CFO of Protagonist Therapeutics, supporting SOX 404(b) implementation during a period of growth
• Held senior finance roles at Symantec and West Coast Bancorp, helping take the bank public on NASDAQ and grow assets from $90 million to $1.5 billion
• Certified Public Accountant (inactive) with a Bachelor of Arts in Accounting from Washington State University

Chad Pawlak, Sr., Chief Executive Officer of Genvor, commented: “Don’s track record of guiding biotechnology companies through transformational growth makes him the ideal financial leader for Genvor at this stage of our development. His deep public company experience combined with his command of complex capital markets and partnership transactions positions him to support the structuring of future joint development agreements across both our agricultural and human health and wellness platforms.”

See the press release at https://genvor.com/press-releases/post?storyId=7340692620742974

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Genvor, Inc. (OTCQB: GNVR) is a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture and human health. Powered by its proprietary BioCypher platform and patented peptides, Genvor is developing and intends to commercialize biological actives for crop protection and plant health alongside consumer-focused peptide solutions for recovery, performance, anti-aging, and daily wellness. Through its technology platforms and future partnerships, Genvor intends to advance a new era of natural, science-based innovation.

Genvor is led by Chief Executive Officer Chad Pawlak, Sr. and Chief Financial Officer Don Kalkofen, with co-founders Dr. Jesse Jaynes and Dr. Clayton Yates bringing decades of peptide research expertise. Learn more at www.genvor.com and about other B2i Digital Featured Companies at https://b2idigital.com/featured-companies.

See the complete Disclosure at https://b2idigital.com/disclaimer.

05/21/2026

The S**C Conference 2026 returns to Westchester Country Club on June 9-10, with two days of programming and, new this year, schedulable 1-on-1 meetings for sponsors and de-S**C targets.

The S**C Conference 2026 returns to the Westchester Country Club in New York for two days of programming on Tuesday and Wednesday, June 9-10, 2026, hosted by DealFlow Events.

The S**C Conference 2026 is a B2i Digital Featured Conference. For more details, please visit: https://b2idigital.com/dealflow-events-spac-conference-2026

The two-day program brings together investment bankers, institutional investors, S**C sponsors, and service professionals from across the S**C and de-S**C ecosystem. Sessions cover regulatory and structural shifts shaping today's market, valuation and PIPE trends, cross-border transactions, litigation and enforcement themes, IR and post-listing market support, and what private targets should evaluate before choosing a S**C partner.

New this year, the conference is offering 1-on-1 meetings that can be scheduled in advance, designed for S**C sponsors and private company executives considering a S**C route to the public markets.

Agenda coverage spans:
- Regulatory clarity and SEC enforcement priorities for S**Cs and de-S**Cs
- Disclosure liability, sponsor and director exposure, and litigation risk management
- Earnout structures and risk-adjusted valuations in today's rationalized market
- Cross-border S**C listings, U.S. liquidity access, and global PIPE participation
- IR strategy, analyst coverage, lock-up dynamics, and post-listing market support
- Governance standards, board independence, and sponsor-promote alignment

DealFlow Events has produced more than 200 conferences, seminars, and webcasts over the past 20 years, with programs recognized for content depth and quality of networking across the financial markets it covers.

Event details and registration are available at https://spacconference.com and https://dealflowevents.com.

A sincere thank you to the DealFlow conference team whose hard work and dedication make events like this possible: Steven Dresner, Phillip LoFaso, Brooke Greiff, PJ Daniels, Lenny La Sala, and Morgan Cropsey. Their efforts behind the scenes deserve every bit of recognition.

About B2i Digital, B2i Digital connects emerging growth companies with sector-focused investors through digital marketing campaigns and a curated network of Featured Companies, Featured Experts, and Featured Conferences.

Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.

Disclosure: B2i Digital, Inc. is a marketing partner of The S**C Conference 2026. B2i Digital is not an affiliate of DealFlow Events and is not authorized to represent or act on behalf of DealFlow Events in any capacity. DealFlow Events has not reviewed or approved the content of this post. Content about any specific company was provided and approved by that company or is available in the public domain.

Address

401 2nd Avenue
New York, NY
10010

Telephone

+12125794844

Website

Alerts

Be the first to know and let us send you an email when B2i Digital posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to B2i Digital:

Shortcuts

Share

Category